Toggle Side Panel
Close search

GUIDE

mRNA Vaccines: Manufacturing Guide, CDMO Services & Market Report

Messenger RNA (mRNA) vaccines and therapeutics have emerged as a transformative force in the pharmaceutical landscape, with the remarkable success of mRNA-based COVID-19 vaccines propelling this technology into the global spotlight.

The mRNA CDMO market plays a vital role in supporting the translation of cutting-edge mRNA research into viable, market-ready therapies. These specialised contract manufacturers provide essential services to biopharmaceutical companies, startups, and research institutions, enabling them to leverage the power of mRNA technology without having to build their own large-scale production capabilities from scratch. 

This report offers insight into the key drivers fuelling the expansion of the mRNA CDMO market, the specific manufacturing challenges, growth drivers, key market players and choosing the right CDMO partner.

While recent news of US funding cuts to mRNA vaccine programs will make an impact, the global mRNA synthesis and manufacturing market is estimated to be worth $ 0.49 billion in 2025 and is likely to grow to $ 0.58 billion by 2035. This follows a sharp drop between 2024 and 2025, due to a reduced demand for COVID-19 vaccines. This data underscores the substantial opportunities for CDMOs specialising in the production and manufacturing of mRNA-based products.

Source- Roots Analysis

mRNA Technology for Disease Treatment

mRNA vaccines and therapeutics represent a novel approach to treating diseases by instructing the body’s own cells to produce therapeutic proteins. This innovative technology harnesses the natural process of protein synthesis within cells to generate specific proteins that can have a therapeutic effect, rather than relying on the direct administration of the proteins themselves.

The transformative potential of mRNA vaccines and treatments spans a wide range of previously untreatable diseases. Rapid advances in biotechnology and molecular medicine now enable the production of nearly any functional protein or peptide in the human body by introducing mRNA as a vaccine or therapeutic agent. This represents a leap forward in precision medicine, with exciting potential for preventing and treating various genetic and hard-to-treat diseases. Additionally, in vitro transcribed mRNA allows for programmable protein production that is faster, more efficient, flexible, and cost-effective compared to traditional methods.

These benefits position mRNA vaccines as the fastest responders in large-scale infectious outbreaks, as seen in the COVID-19 pandemic. Researchers have long aimed to improve the stability, immunogenicity, translation efficiency, and delivery systems for mRNA, and significant strides in molecular biology, RNA technology, vaccinology, and nanotechnology are bringing these goals closer to realization. This review provides a comprehensive overview of mRNA-based therapeutics, covering their principles, production, applications, and challenges. It underscores the importance of mRNA optimization and advanced delivery systems, addressing both the hurdles and opportunities in developing mRNA into a versatile tool for combating genetic disorders, infectious diseases, cancer, and other complex health challenges.

Source- Nature

How mRNA Vaccines and Therapeutics Work

The core principle behind mRNA vaccines and therapeutics is the use of synthetic mRNA molecules to provide the genetic instructions for the production of desired proteins within the target cells. Unlike traditional small-molecule drugs or protein-based therapies, mRNA therapeutics do not directly introduce the therapeutic protein into the body. Instead, they deliver the mRNA, which then acts as a template for cells to produce the relevant protein.

This process begins with the synthetic design of an mRNA molecule that encodes the genetic sequence for the target protein. The mRNA is then packaged and delivered to the target cells, often using specialised delivery mechanisms such as lipid nanoparticles (LNPs) or viral vectors. Once inside the cells, the mRNA is translated by the cellular machinery, leading to the production and secretion of the therapeutic protein. This approach allows the body’s own cells to become the “factories” for generating the desired proteins, offering an efficient and targeted therapeutic solution.

The 5 mRNA Production Steps

The simplicity, scalability, and speed of mRNA production makes it a promising platform for drug and vaccine development. Unlike traditional vaccine development methods, which may take years, mRNA vaccines can be developed in a matter of months.

Step 1: mRNA Template Design – The process begins with designing a plasmid DNA (pDNA) template that includes an RNA polymerase promoter and a specific mRNA sequence. This template is then amplified using expression systems like E. coli bacteria and linearized for better integration. To ensure the desired immune response, accuracy is crucial at this stage. Protecting the sequence from impurities helps maintain its stability and effectiveness in gene expression and translation.

Step 2: In vitro Transcription (IVT) – After the DNA template is prepared, the linear plasmid DNA is transcribed into mRNA using IVT. Unlike in vivo transcription, this method does not use animal-derived materials. RNA synthesis is achieved through an enzymatic reaction involving RNA polymerase and nucleotides. Post-transcription, the mRNA is capped to prevent degradation, enhancing its stability and translation efficiency. This step ensures the mRNA remains intact and functional.

Step 3: mRNA Purification – Once transcription is complete, the DNA template must be removed to isolate the mRNA. Various chromatography and filtration techniques, including tangential flow filtration (TFF), are used to purify the mRNA. This step is essential to separate the mRNA from the DNA template and eliminate any impurities that could interfere with the production process, ensuring a high-quality mRNA product.

Step 4: mRNA Characterization – Throughout production, efficient analytical tools are vital to ensure the mRNA remains unaltered and safe for use. mRNA molecules are sensitive to environmental stressors such as heat, light, and ribonucleases, which can lead to degradation and reduced efficacy. Techniques like mass spectrometry, RNase mapping, and RNA-sequence mapping are used to assess quality and minimize risks of degradation. Ensuring mRNA integrity is crucial as the technology sees increased interest, notably for mRNA vaccines.

Step 5: Formulation and Stability Optimization – The final step in mRNA production involves enhancing mRNA stability and preparing it for delivery. Due to its low stability, mRNA products require frozen storage and protective measures during manufacturing. LNPs are often used to deliver the mRNA safely to immune cells and stabilize the formulation. After formulation, the product is sterilized, aseptically filled, and packaged for storage or transport, ensuring it remains effective until it reaches the end user.

Source- Single Use Report

Therapeutic Applications of mRNA Technology

The adaptability of mRNA technology has broadened its use across various therapeutic areas, including:

  • Vaccines for Infectious Diseases: The success of mRNA COVID-19 vaccines by Pfizer-BioNTech and Moderna highlights mRNA’s potential to swiftly develop effective vaccines for emerging diseases
  • Cancer Immunotherapies: mRNA can encode tumour-associated antigens or activate the immune system to target cancer cells, creating new possibilities in cancer treatment
  • Rare Genetic Disorder Treatments: mRNA therapies offer potential for correcting genetic mutations in rare diseases, bringing hope to patients with previously limited options
  • Autoimmune Disease Therapies: By modulating immune responses, mRNA holds promise for treating autoimmune conditions like multiple sclerosis and rheumatoid arthritis
  • Cardiovascular Disease Treatments: Researchers are exploring mRNA-based approaches to target genes linked to heart diseases, aiming to develop new cardiovascular therapies
  • Neurological Disorder Therapies: mRNA is also being studied for treating neurological disorders such as Alzheimer’s and Parkinson’s disease

Pipeline and Product Development Trends

The mRNA vaccines and therapeutics market has seen significant progress, largely fuelled by the ground breaking success of mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna. These achievements have showcased the potential of mRNA technology and driven substantial investment and research momentum.

Beyond COVID-19 vaccines, the mRNA therapeutics pipeline has grown rapidly, with a variety of candidate therapies now in clinical development across multiple therapeutic areas. Key examples include:

  • Approved COVID-19 vaccines from Pfizer-BioNTech and Moderna
  • Numerous mRNA vaccines and therapies in clinical trials for cancer, genetic disorders, infectious diseases, and other indications

These developments and pipeline candidates highlight the fast-changing mRNA vaccine and therapeutics landscape—and the increasing role of CDMOs in turning cutting-edge research into viable, market-ready treatments.

Drivers of the mRNA Technology CDMO Market

  • Growing Investment in R&D
    • Success of COVID-19 mRNA vaccines has boosted investor confidence, leading to substantial funding for mRNA technology
    • Expanding mRNA therapeutics pipeline with candidates for various diseases attracts more investment
    • Partnerships between biopharmaceutical companies and CDMOs accelerate mRNA development with significant financial backing
    • Government funding worldwide supports mRNA research and development efforts, benefiting the CDMO ecosystem
  • Expanding Therapeutic Applications
    • mRNA technology is expanding beyond vaccines to treat cancer, genetic disorders, autoimmune diseases, cardiovascular, and neurological conditions
    • The adaptability of mRNA makes it attractive for addressing diverse medical needs
    • CDMOs are essential in scaling mRNA synthesis, formulation, and manufacturing, enabling companies to adopt mRNA without building in-house facilities

These drivers foster a supportive environment for mRNA CDMOs, fueling market growth and establishing them as key players in advancing mRNA-based therapies.

“The mRNA therapeutics market is fast expanding, driven by the rise of complex diseases and the expanding role of mRNA technologies and applications in oncology. The speed at which the COVID-19 vaccines moved through clinical trials and successful regulatory approval has positively influenced how risk is viewed in the industry,” comments Maria Colombo, PhD, Director, R&D – Nucleic Acid Services, Sean Essex, Global SME (mRNA/LNP), and Enrico Steiner, Director, Site Leader, mRNA, Pharma Services, Thermo Fisher Scientific.

As a consequence, there are other novel and breakthrough mRNA therapies moving swiftly from clinical trials toward commercial approval – areas such as therapeutic protein replacement and therapeutic antibody production and in vivo and ex vivo genome-editing. Examples include treatment for sickle cell anaemia, vaccines for infectious diseases like malaria, HIV, Rabies, Mpox, and other diseases/conditions, where there is a significant unmet need. Pressure on the pharmaceutical and biotech industries to deliver potentially ground breaking mRNA drugs in a timely manner for patients has significantly increased the demand for mRNA CDMO services. 

To be successful, CDMOs themselves have had to rapidly evolve with the dynamic landscape of mRNA vaccines and therapeutics. The advent of AI presents significant opportunities and challenges for mRNA therapeutic CDMOs. Embracing new technologies such as continuous manufacturing, real-time monitoring, and analytics is essential to streamline and optimize development and manufacturing processes, thereby reducing program timelines. Additionally, there is a need to build flexibility in production capabilities to accommodate a range of manufacturing scales, from personalized therapies to large-scale commercial batches.

Adapting to new modalities beyond mRNA, such as self-amplifying RNA (saRNA) and circular RNA (cirRNA), and expanding service offerings for both manufacturing and robust analytical characterization methods is critical. These advancements must be achieved while maintaining compliance with stringent regulatory requirements. To combat these challenges and stay ahead of the curve, CDMOs are increasing their investment in innovation (R&D); for example, strengthening versatile LNP assets via development of proprietary lipids or partnerships to access proprietary lipid libraries. Also, a rising number of mergers and acquisitions/strategic partnerships point toward the CDMOs’ goals of offering the best “end-to-end” services for their biopharma sponsors.

Manufacturing Considerations for mRNA Vaccine and Therapeutic Production

mRNA manufacturing is technically demanding and operationally distinct from most established biologic or small molecule manufacturing platforms. Understanding these distinctions is essential before engaging a contract manufacturing partner.

What makes mRNA drug substance manufacturing uniquely challenging? The production process combines biochemical synthesis (IVT), complex purification (tangential flow filtration, chromatography), and nanotechnology-based formulation (LNP encapsulation) — all under GMP conditions. Each unit operation introduces potential failure modes that require validated analytical methods, experienced technical teams, and purpose-built facility infrastructure.

Key technical and operational considerations include the following:

  • Plasmid DNA supply chain: The IVT template must be produced under GMP conditions and rigorously characterized. CDMOs offering integrated pDNA and mRNA manufacturing reduce handoff risk but require robust quality agreements between units.
  • IVT optimization: Yield and quality of the mRNA transcript depend on enzyme lots, nucleotide concentrations, and reaction conditions. Batch-to-batch variability in IVT is a known challenge that requires stringent in-process controls.
  • Capping and modification: Cotranscriptional capping (e.g., CleanCap technology) versus post-transcriptional enzymatic capping affects potency, immunogenicity, and manufacturing cost. Modified nucleosides (e.g., N1-methylpseudouridine) are now standard for reducing innate immune activation in many clinical programs.
  • Purification: Removal of residual dsRNA, truncated transcripts, and template DNA requires validated chromatographic and filtration methods. Impurity profiles must be characterized and linked to clinical product.
  • LNP formulation: Microfluidic or T-junction mixing of mRNA with ionizable lipid, phospholipid, cholesterol, and PEG-lipid must produce nanoparticles of defined size, polydispersity index (PDI), and encapsulation efficiency. This step is highly sensitive to mixing parameters, excipient ratios, and temperature.
  • Fill-finish and storage: Frozen bulk storage at -20°C to -80°C is standard for most LNP products. Lyophilization development is an active area that could expand shelf life and distribution reach.
  • Analytical characterization: Product quality attributes — integrity, purity, potency (in vitro translation assay), particle size, zeta potential, encapsulation efficiency, residual impurities — require a comprehensive suite of analytical methods, many of which are still being harmonized across the industry.

Key Criteria for Selecting an mRNA Manufacturing CDMO

When evaluating CDMO partners for mRNA drug substance or drug product manufacturing, procurement and CMC teams should assess the following criteria:

  1. GMP track record for nucleic acid manufacturing — Has the facility produced GMP mRNA for IND-enabling studies, Phase I/II, or commercial supply? Inspect manufacturing history and batch release records where available.
  2. Proprietary or licensed LNP platform — Does the CDMO offer a validated LNP delivery platform? Understand the IP landscape — what freedom to operate does the partner have, and what licenses may be required for your program?
  3. Integrated pDNA manufacturing capability — In-house plasmid DNA production reduces supply chain risk and quality handoff complexity. Confirm GMP pDNA capacity and turnaround time.
  4. Analytical capability and method development expertise — Confirm access to validated methods for particle characterization, mRNA integrity analysis (CE or bioanalyzer), potency assays, and residual impurity testing.
  5. Regulatory submission experience — Has the CDMO supported IND, CTA, BLA, or MAA filings for mRNA products? Request examples of regulatory interaction outcomes relevant to mRNA programs.
  6. Scale-up infrastructure — Assess equipment fit between clinical and commercial scale (microfluidic versus larger-scale impingement jet mixing), and confirm whether scale-up has been validated internally or only at laboratory scale.
  7. Cold chain and logistics capability — Confirm frozen bulk storage capacity, temperature-monitored shipping capability, and experience with international cold chain logistics for clinical supply.
  8. Technology transfer process and timelines — Understand the CDMO’s structured technology transfer process, expected lead times, and how previous tech transfer projects have been managed.

Red Flags to Watch for When Evaluating mRNA CDMO Partners

Pharma and biotech teams should treat the following as warning signs during due diligence:

  • Inability to provide references from prior mRNA GMP campaigns at a relevant scale
  • Vague or unresolved LNP IP licensing position that could affect your program’s freedom to operate
  • Limited in-house analytical capability, requiring significant outsourcing of critical quality attribute testing
  • Lack of dedicated mRNA production suites, with shared equipment presenting contamination or scheduling risks
  • Absence of a formal technology transfer protocol or documented process development playbook
  • Regulatory audit findings related to data integrity, aseptic processing, or environmental monitoring in recent inspections

5 Questions to Ask Shortlisted mRNA CDMOs Before Signing a Contract

  1. Can you provide batch records and release data from comparable GMP mRNA campaigns, and what were the key quality outcomes? This tests actual GMP experience and transparency.
  2. What is your LNP formulation platform, and what is the current IP and licensing position relative to our target indication and delivery route? This surfaces potential commercial risk early.
  3. How do you handle raw material variability — particularly lipid components and capping enzyme lots — and what controls are in place to ensure batch-to-batch consistency? This probes depth of process understanding.
  4. What is your regulatory track record for mRNA programs? Have you supported or authored any IND/CTA, Phase III, or BLA/MAA submissions for mRNA drug products? This verifies regulatory submission capability and experience.
  5. What does your technology transfer process look like, and what is a realistic timeline from contract execution to first GMP batch? This sets expectations and identifies potential bottlenecks before commitment.

Frequently Asked Questions (FAQ)

What are mRNA therapeutics?

mRNA therapeutics use synthetic mRNA to instruct cells to produce specific proteins for therapeutic purposes—offering a fast, targeted, and versatile alternative to traditional drugs.

How is mRNA manufactured for vaccines and therapeutics?

mRNA for vaccines and therapeutics is produced through an enzymatic, cell-free process called in vitro transcription (IVT). A linearized plasmid DNA template encoding the target sequence is incubated with an RNA polymerase and nucleotide building blocks, generating the mRNA strand. The transcript is then capped (to mimic natural mRNA and improve stability), purified to remove impurities including residual DNA and double-stranded RNA, and formulated — typically by encapsulation within lipid nanoparticles — before filling into vials or cartridges. The entire process is conducted under GMP conditions to meet regulatory requirements for clinical and commercial use.

What CDMOs specialize in mRNA manufacturing?

A growing number of contract development and manufacturing organizations have invested in dedicated mRNA manufacturing infrastructure, particularly following the COVID-19 vaccine programs. CDMOs specializing in mRNA contract manufacturing typically offer integrated services spanning plasmid DNA production, IVT-based mRNA synthesis, LNP formulation, fill-finish, and analytical development. The most capable partners offer validated LNP delivery platforms, GMP experience across clinical stages, and a track record of regulatory submissions for mRNA drug products. PharmaSource provides a curated, independently verified directory of CDMOs offering mRNA manufacturing services, including capability data and regulatory history.

What is lipid nanoparticle (LNP) formulation in mRNA manufacturing?

Lipid nanoparticle (LNP) formulation is the process of encapsulating mRNA within a nanoparticle composed of four lipid components: an ionizable lipid (which facilitates endosomal escape), a phospholipid (which provides structural integrity), cholesterol (which stabilizes the particle), and a PEG-lipid (which controls particle size and reduces aggregation). The mRNA and lipid components are rapidly mixed — using microfluidic or impingement jet mixing technology — at controlled flow rates and ratios to produce nanoparticles typically between 80–200 nanometers in diameter. LNP formulation is one of the most technically sensitive steps in mRNA drug product manufacturing, and differences in lipid composition, ionizable lipid selection, and mixing parameters can significantly affect potency, tolerability, and immunogenicity.

What are the steps in mRNA production?

  1. Template Design
  2. In vitro Transcription (IVT)
  3. mRNA Purification
  4. Characterization
  5. Formulation & Stability Optimization

What should companies look for in an mRNA CDMO partner?

Key factors:

  • Proven quality and compliance
  • Scalability and flexibility
  • Strategic collaboration
  • Regional production capabilities
  • Comprehensive service offerings

What are the main challenges for CDMOs in this space?

  • Navigating evolving regulations
  • Scaling during public health crises
  • Ensuring supply chain resilience
  • Managing IP rights and licensing
  • Balancing cost vs. pricing pressure

Recent mRNA CDMO Announcements:

Download the full CDMO Live Report for 50 pages of insights and best practices in external manufacturing.

More Category Guides